Oculis Holding AG (OCS) Interest Coverage Ratio (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Interest Coverage Ratio came in at 658.42 in Q1 2026, down 60.44% year-on-year from 1664.5 in Q1 2025, and up 14.88% quarter-over-quarter from 573.14 in Q4 2025.
Oculis Holding AG (OCS) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
Oculis Holding AG's Interest Coverage Ratio history runs 5 years deep, the most recent figure standing at 658.42 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio fell 60.44% year-over-year to 658.42 in Q1 2026; TTM through Mar 2026 was 580.73, a 44.98% decrease from a year earlier, with the FY2025 full-year figure at 98.05, up 14.42% from the prior year.
- Interest Coverage Ratio rose to 658.42 in Q1 2026 per OCS's latest filing, from 573.14 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 3448.0 in Q1 2023 and bottomed at 10.02 in Q3 2023.
- The 5-year median for Interest Coverage Ratio is 615.78 (2025), against an average of 857.28.
- Across the five-year window, Interest Coverage Ratio sank 104.08% in 2023 and soared 14196.88% in 2024, its largest moves.
- Year by year, Interest Coverage Ratio stood at 1.73 in 2022, then soared by 637.07% to 9.29 in 2023, then surged by 14196.88% to 1327.69 in 2024, then plunged by 56.83% to 573.14 in 2025, then climbed by 14.88% to 658.42 in 2026.
- Per Business Quant, the three latest OCS Interest Coverage Ratio figures stand at 658.42 (Q1 2026), 573.14 (Q4 2025), and 0.72 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 3.88 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 658.42 |
| Dec 31, 2025 | 573.14 |
| Sep 30, 2025 | 0.72 |
| Jun 30, 2025 | 1,888.00 |
| Mar 31, 2025 | 1,664.50 |
| Dec 31, 2024 | 1,327.69 |
| Sep 30, 2024 | 1.07 |
| Jun 30, 2024 | 1,606.07 |
| Mar 31, 2024 | 1,532.80 |
| Dec 31, 2023 | 9.29 |
| Sep 30, 2023 | -10.02 |
| Jun 30, 2023 | 767.50 |
| Mar 31, 2023 | 3,448.00 |
| Dec 31, 2022 | -1.73 |
| Sep 30, 2022 | 245.46 |
| Jun 30, 2022 | 5.55 |